Oxford Drug Design has raised nearly $2m (£1.5m) of private investment to enable it to progress a novel antibacterial programme and continue to build its proprietary platform.
The funding, which will also help finance the company’s commercial and research and development (R&D) activities, was supported by both existing shareholders including IP Group plc as well as new investors including Busolantix Investment SA, O2h Ventures and a number of Business Angels.

Oxford Drug Design will continue to build and utilise its proprietary technology platform in cheminformatics, 3D molecular similarity and computer-aided drug design, in parallel with progressing the antibacterial programme.